NCT05390515 Psoriatic Immune Response to Tildrakizumab
| NCT ID | NCT05390515 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, San Francisco |
| Condition | Psoriasis Vulgaris |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2028-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 10 participants in total. It began in 2022-09-01 with a primary completion date of 2028-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Patients with moderate-severe psoriasis or \> 5% body surface area affected. Exclusion Criteria: * taking systemic immunosuppressives in the last 4 weeks * pregnancy * severe immunodeficiency (either from genetic or infectious causes). * tuberculosis or other active serious infection * active systemic malignancy. * breast-feeding * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Contact & Investigator
Raymond Cho, MD, PhD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT05390515 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Psoriasis Vulgaris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05390515 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05390515 currently recruiting?
Yes, NCT05390515 is actively recruiting participants. Contact the research team at rashes@ucsf.edu for enrollment information.
Where is the NCT05390515 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT05390515 clinical trial?
NCT05390515 is sponsored by University of California, San Francisco. The principal investigator is Raymond Cho, MD, PhD at University of California, San Francisco. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.